Sign in Register

Drug class

Immunosuppressants - mTOR Inhibitors

Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway. Read more about Immunosuppressants - mTOR Inhibitors

37 drugs in this class 29 manufacturers

Related classes & indications

Alkylating AgentsOncology & immunomodulators · 192 prescription drugs Antirheumatic Agents (DMARDS, non-Biologic)Oncology & immunomodulators · 179 prescription drugs

Showing 1–9 of 37 drugs

Sort

AFINITOR (everolimus)

ANTINEOPLASTIC - MTOR KINASE INHIBITORS · METASTATIC RENAL CELL CARCINOMA ·+6

Novartis Pharmaceuticals

ZORTRESS (everolimus)

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

Novartis Pharmaceuticals

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

GREENSTONE LLC.

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

ZYDUS PHARMACEU

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

DR.REDDY'S LAB

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

GREENSTONE LLC.

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

AHP

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

Amneal Pharmaceuticals

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

GREENSTONE LLC.

Filter & compare in the drug finder → Opens the drug finder with Immunosuppressants - mTOR Inhibitors preselected. Add indication or manufacturer filters there.

About Immunosuppressants - mTOR Inhibitors.

Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway.

Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle.

Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients.

They are also utilized to manage specific non-malignant proliferative conditions, such as lymphangioleiomyomatosis, and serve as non-nephrotoxic alternatives or adjuncts to calcineurin inhibitors.

nih.gov
Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients
nih.gov
Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway
nih.gov
Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients
nih.gov
Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle
nih.gov
Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle
nih.gov
Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients
nih.gov
They are also utilized to manage specific non-malignant proliferative conditions, such as lymphangioleiomyomatosis, and serve as non-nephrotoxic alternatives or adjuncts to calcineurin inhibitors